Financial Performance - The company's operating revenue for Q3 2025 was ¥127,309,563.39, a decrease of 5.63% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of ¥7,845,520.13, representing an increase in loss of 26.32% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥14,740,744.18, down 33.71% from the previous year[5] - The basic earnings per share for the period was -¥0.05, an increase in loss of 16.67% compared to the same period last year[5] - The total comprehensive loss for the period was ¥18,960,583.26, a decrease in loss of 50.82% compared to the previous year[10] - The net profit for the current period was a loss of ¥18,960,583.26, an improvement from a loss of ¥38,555,558.15 in the previous period, indicating a reduction in losses by 50.8%[25] - The total comprehensive income for the current period was -¥18,960,583.26, compared to -¥38,555,558.15 in the previous period, showing a significant reduction in comprehensive losses[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,691,118,875.31, a decrease of 3.56% from the end of the previous year[5] - As of September 30, 2025, total assets amounted to CNY 1,691,118,875.31, a decrease from CNY 1,753,496,741.59 at the beginning of the period[21] - Current assets totaled CNY 865,834,738.26, down from CNY 892,800,836.11 at the beginning of the period[20] - Total liabilities decreased to CNY 562,836,431.32 from CNY 574,653,606.82 at the beginning of the period[21] - The company reported a decrease in retained earnings to CNY 283,135,695.71 from CNY 300,862,910.92[21] - The company’s total equity decreased to CNY 1,128,282,443.99 from CNY 1,178,843,134.77[22] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥8,233,130.30, a significant increase in outflow of 75.92% year-on-year[5] - Operating cash flow improved by 75.92%, from -34,183,808.79 to -8,233,130.30, primarily due to reduced employee compensation payments[12] - Net cash flow from investment activities increased by 86.85%, from -36,488,836.40 to -4,798,298.05, attributed to decreased payments for infrastructure and renovation as subsidiary construction nears completion[12] - Cash flow from financing activities decreased significantly by 1,523.45%, from 2,391,892.86 to -34,047,427.74, due to a reduction in new borrowings compared to the previous year[12] - The ending cash and cash equivalents balance decreased by 42.45%, from 112,599,166.94 to 64,804,631.88, primarily due to a reduction in cash at the beginning of the year[12] - The net cash flow from operating activities was negative at ¥8,233,130.30, an improvement from a negative cash flow of ¥34,183,808.79 in the previous period[27] - Cash and cash equivalents at the end of the period totaled ¥64,804,631.88, down from ¥112,599,166.94 at the end of the previous period[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 25,429, with no preferred shareholders having restored voting rights[13] - The largest shareholder, Ding Xiangpeng, holds 23.68% of shares, totaling 43,570,280, with 32,677,710 shares under lock-up[13] - The company repurchased a total of 4,690,480 shares, representing 2.55% of the total share capital, through a dedicated repurchase account[14] - The total number of restricted shares at the beginning of the period was 37,314,435, with 364,225 shares released during the period, resulting in a total of 37,678,660 restricted shares at the end[15] - The company has a policy that allows executives to transfer no more than 25% of their shares annually, with a six-month lock-up period after leaving their positions[15] Operational Developments - The company reported a significant increase in prepayments, which rose by 203.29% to ¥16,139,654.18 due to increased advance payments for new contracts[9] - The company experienced a 69.18% decrease in interest income, totaling ¥373,182.28, primarily due to a reduction in bank deposit balances[10] - The company’s weighted average return on net assets was -0.72%, an improvement of 0.25% compared to the previous year[5] - Research and development expenses increased to ¥16,393,442.35 from ¥15,059,102.69, representing an increase of 8.83%[23] - The company’s subsidiary, Xinjiang Guolin New Materials Co., Ltd., underwent maintenance on its 25,000 tons/year high-quality glyoxylic acid production line from June 3, 2025, and resumed production on August 18, 2025, after passing safety tests[16] - The European Commission imposed a final anti-dumping duty of 57.30% on glyoxylic acid produced by Xinjiang Guolin, effective from September 22, 2025, with a five-year implementation period[17] - The company is planning a major asset restructuring to acquire 91.07% of Xinjiang Kailianjie Petrochemical Co., Ltd. using self-funding and bank loans, with the transaction still in the preliminary planning stage[18] Cost and Revenue Analysis - Total operating revenue for the current period reached ¥386,104,630.91, an increase of 11.83% compared to ¥345,325,198.06 in the previous period[23] - Total operating costs amounted to ¥393,999,401.90, up from ¥360,838,199.01, reflecting a year-over-year increase of 9.14%[23] - The company recorded other income of ¥10,717,996.33, significantly higher than ¥4,408,796.84 in the previous period, marking an increase of 143.5%[23] - The company reported a basic and diluted earnings per share of -¥0.10, an improvement from -¥0.19 in the previous period[25]

Financial Performance - The company's revenue for Q3 2025 was ¥271,231,009.48, a decrease of 1.45% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of ¥1,699,666.95, representing a decline of 67.29% year-over-year[5] - Total operating revenue for Q3 2025 was CNY 776,063,650.82, a decrease of 6.25% from CNY 827,730,115.22 in the previous year[19] - Net profit for the period was a loss of CNY 15,079,551.28, compared to a profit of CNY 14,079,134.06 in the same period last year[20] - Basic and diluted earnings per share were both CNY -0.17, compared to CNY 0.16 in the previous year[20] Cash Flow - The net cash flow from operating activities was negative at ¥42,503,324.92, a significant decrease of 361.83% compared to the previous year[9] - Cash inflow from operating activities totaled CNY 877,071,606.82, a decrease from CNY 912,610,946.51 in the prior year[21] - The net cash flow from operating activities was -$42.5 million, a decrease from $16.2 million in the previous period[22] - The net cash flow from investment activities was -$422.5 million, compared to a positive $78.4 million in the prior period[22] - The net increase in cash and cash equivalents was -$496.9 million, contrasting with a positive increase of $35.4 million in the prior period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,223,819,725.65, down 3.71% from the end of the previous year[5] - Total assets decreased to CNY 2,223,819,725.65 from CNY 2,309,420,442.59, reflecting a decline of approximately 3.7%[18] - Total liabilities decreased to CNY 197,594,234.70 from CNY 241,515,885.28, a reduction of about 18.2%[18] - The company’s total equity attributable to shareholders was ¥2,026,225,490.95, down 2.02% from the previous year[5] - Shareholders' equity attributable to the parent company was CNY 2,026,225,490.95, down from CNY 2,067,904,557.31, a decrease of approximately 2%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,893[10] - The largest shareholder, Leng Zhaowu, holds 33.09% of shares, totaling 28,674,000 shares[10] - The total number of restricted shares held by major shareholders at the end of the period is 29,748,000 shares[12] - The company plans to repurchase shares using between 25 million to 50 million RMB, with a maximum price of 45 RMB per share, within 12 months[13] - The company has repurchased a total of 927,600 shares, representing 1.07% of the total share capital, for a total payment of 25,987,076 RMB[13] Operational Costs and Expenses - Total operating costs amounted to CNY 811,539,307.02, down 3.4% from CNY 839,957,828.31 year-over-year[19] - Research and development expenses increased to CNY 47,613,035.52 from CNY 44,808,310.21, reflecting a growth of about 6.2%[19] - The company reported a decrease in financial expenses by 76.07%, attributed to reduced deposit interest[8] Cash and Cash Equivalents - As of September 30, 2025, the total cash and cash equivalents amount to 337,216,278.43 RMB, down from 840,157,413.87 RMB at the beginning of the period[16] - The ending balance of cash and cash equivalents was $335.0 million, down from $428.0 million at the end of the previous period[22] Other Information - The company has not yet audited its third-quarter financial report[23] - The company will implement new accounting standards starting in 2025[24]

Financial Performance - The company's operating revenue for Q3 2025 was ¥81,940,493.84, a decrease of 7.95% compared to the same period last year, and a decline of 27.65% year-to-date [5]. - The net profit attributable to shareholders was -¥23,679,185.66, representing a 17.07% increase in loss year-over-year, and a 35.52% increase in loss year-to-date [5]. - The basic earnings per share for the period was -¥0.04, a 20.00% increase in loss compared to the previous year, and a 28.57% increase in loss year-to-date [5]. - Total revenue for the current period was ¥206,504,557.27, a decrease of 27.6% compared to ¥285,424,385.91 in the previous period [20]. - Net loss for the current period was ¥59,712,575.26, compared to a net loss of ¥40,960,360.00 in the previous period, representing a 45.8% increase in losses [21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥756,982,089.32, down 13.64% from the end of the previous year [5]. - The total assets decreased to ¥756,982,089.32 from ¥876,513,128.42, reflecting a decline of 13.6% [19]. - Total liabilities decreased to ¥142,729,476.37 from ¥187,995,626.61, a reduction of 24.0% [19]. - The company’s total current assets decreased from 725,662,174.89 RMB to 618,650,749.86 RMB, a decline of approximately 14.7% [17]. - The company’s total non-current assets include fixed assets valued at 13,456,496.58 RMB, down from 15,730,676.67 RMB [17]. Cash Flow - The net cash flow from operating activities was -¥48,070,123.06, an improvement of 47.60% compared to the previous period [11]. - Operating cash flow for the current period was -48,070,123.06 CNY, an improvement from -91,734,169.77 CNY in the previous period, indicating a reduction in cash outflow [23]. - Total cash inflow from operating activities decreased to 260,059,395.47 CNY, down 13.2% from 299,474,074.60 CNY in the prior period [23]. - Cash outflow from operating activities also decreased to 308,129,518.53 CNY, down 21.2% from 391,208,244.37 CNY year-over-year [23]. - The ending cash and cash equivalents balance was 299,342,848.39 CNY, down from 330,509,140.14 CNY in the previous period [24]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 34,148 [12]. - The largest shareholder, Nanchang Economic and Technological Development Zone Zhongwen Xushun Enterprise Management Partnership, holds 22.88% of shares, totaling 144,926,089 shares [12]. Research and Development - Research and development expenses decreased by 56.36% to ¥12,619,980.08, primarily due to reduced revenue and gross profit [10]. - Research and development expenses were ¥12,619,980.08, down 56.3% from ¥28,920,146.25 in the previous period [20]. Inventory and Receivables - The company reported a significant increase in inventory by 111.80% to ¥13,592,372.92, attributed to increased contract performance costs [9]. - Accounts receivable decreased from 227,416,183.88 RMB to 196,511,424.33 RMB, a reduction of about 13.6% [17]. - Inventory increased from 6,417,484.39 RMB to 13,592,372.92 RMB, an increase of approximately 111.9% [17]. Investment and Financing Activities - The company experienced a 136.35% increase in investment losses, amounting to -¥4,530,875.14, due to increased losses from joint ventures [10]. - Investment activities generated a net cash outflow of -15,934,108.54 CNY, compared to a net inflow of 10,392,050.71 CNY in the previous period [23]. - Financing activities resulted in a net cash outflow of -12,630,606.33 CNY, an improvement from -23,016,485.42 CNY in the previous period [24]. - Total cash inflow from financing activities increased to 2,760,000.00 CNY, up 40.8% from 1,960,000.00 CNY in the prior period [24].

海伦钢琴股份有限公司 2025 年第三季度报告 证券代码：300329 证券简称：海伦钢琴 公告编号：2025-036 海伦钢琴股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 海伦钢琴股份有限公司 2025 年第三季度报告 项目 本报告期金额 年初至报告期期末金额 说明 非流动性资产处置损益（包 括已计提资产减值准备的冲 销部分） -175,322.25 5,486.92 计入当期损益的政府补助 （与公司正常经营业务密切 相关、符合国家政策规定、 按照确定的标准享有、对公 司损益产生持续影响的政府 补助除外） 5,900.00 22,500.00 除上述各项之外的其他营业 外收入和支出 -80,7 ...

汕头市超声仪器研究所股份有限公司 2025 年第三季度报告 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 一、主要财务数据 证券代码：301602 证券简称：超研股份 公告编号：2025-049 汕头市超声仪器研究所股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 增减 | | 上年同期增减 | | 营业收入（元） | 69,929,018.69 | -31.07% | 253,606,900.34 | -2.90% ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥142,894,059.82, a decrease of 1.68% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2025 was ¥11,240,854.12, down 25.54% year-on-year[4] - The basic earnings per share for Q3 2025 was ¥0.0753, a decline of 24.66% compared to the previous year[4] - Total revenue for the current period was ¥448,153,812.23, a decrease of 7.1% compared to ¥482,478,245.61 in the previous period[21] - Operating profit for the current period was ¥62,136,962.15, down from ¥67,415,015.55 in the previous period, reflecting a decline of 7.0%[22] - Net profit for the current period was ¥53,542,383.94, compared to ¥58,192,322.27 in the previous period, representing a decrease of 8.8%[23] - Basic and diluted earnings per share were both ¥0.35, down from ¥0.39 in the previous period[23] Cash Flow - The net cash flow from operating activities increased by 58.30% to ¥101,695,494.70, attributed to enhanced management measures and increased collection efforts[10] - Operating cash inflow for the current period was $478,855,866.74, an increase of 7.4% from $447,301,886.28 in the previous period[24] - Net cash flow from operating activities reached $101,695,494.70, up 58.4% compared to $64,241,043.42 in the prior period[24] - Cash outflow from investment activities totaled $40,702,215.71, an increase from $35,241,563.33 in the previous period[25] - Net cash flow from investment activities was -$37,901,495.00, a decline from $9,913,543.36 in the prior period[25] - Cash inflow from financing activities was $16,000,000.00, down from $30,000,000.00 in the previous period[25] - Net cash flow from financing activities was -$64,258,454.18, an improvement from -$86,833,342.76 in the prior period[25] - The ending cash and cash equivalents balance was $279,043,781.31, down from $297,843,308.22 in the previous period[25] - The company received $20,829,750.47 in tax refunds, a decrease from $23,481,703.80 in the previous period[24] - Cash paid for purchasing goods and services was $231,530,579.63, a decrease from $241,312,650.63 in the prior period[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,007,243,647.55, a decrease of 1.22% from the end of the previous year[4] - Total assets at the end of the period were ¥1,007,243,647.55, down from ¥1,019,697,481.30 at the beginning of the period, a decrease of 1.2%[19] - Total liabilities decreased to ¥133,521,726.47 from ¥139,835,944.16, a reduction of 4.5%[19] - Total equity attributable to shareholders decreased to ¥869,513,771.67 from ¥876,706,699.93, a decline of 0.8%[20] - The company's contract liabilities increased by 140.17% to ¥4,960,190.10, reflecting an increase in advance payments for goods[9] - The company's intangible assets rose by 54.82% to ¥38,793,110.58, due to the acquisition of land use rights by a subsidiary[9] - The company reported a decrease in other payables by 1316.93% to ¥16,113,862.02, primarily due to accrued dividends[9] Shareholder Information - Total number of common shareholders at the end of the reporting period is 11,619[11] - The largest shareholder, Suzhou Jujie Investment Co., Ltd., holds 52.72% of shares, totaling 78,665,950 shares[11] - The top ten shareholders hold a significant portion of the company's shares, with the top three being family members of the largest shareholder[12] - The company has a total of 0 preferred shareholders at the end of the reporting period[13] - The company has not reported any changes in the status of restricted shares during the reporting period[14] Investment and Expenses - The company reported a significant increase in investment income, rising 4849.70% to ¥658,344.50 due to increased returns from associated companies[9] - The company's financial expenses decreased by 56.43% to -¥1,736,232.19, primarily due to reduced interest income[9] - Research and development expenses for the current period were ¥22,091,010.09, slightly up from ¥21,229,154.18 in the previous period[21] - The company reported a financial cost reduction, with a net financial expense of -¥1,736,232.19 compared to -¥3,985,240.07 in the previous period[21] Other Financial Information - The company did not undergo an audit for the third quarter financial report[26] - Deferred income tax liabilities increased to ¥44,400.00 from zero, indicating a new liability recognized during the period[19] - Accounts receivable decreased from ¥109,578,413.33 to ¥106,312,038.41, reflecting a decline of approximately 2.08%[18] - Inventory decreased significantly from ¥122,706,095.67 to ¥97,894,479.79, a reduction of about 20.19%[18] - Long-term equity investments increased from ¥55,128,564.34 to ¥66,176,908.84, representing a growth of approximately 20.09%[18] - Non-current assets total ¥491,498,131.38, slightly down from ¥494,348,753.74[18]

Financial Performance - The company's revenue for the third quarter reached ¥62,071,829, representing a 127.41% increase compared to the same period last year[5] - The net profit attributable to shareholders was -¥118,839,675.56, a 6.89% improvement year-over-year[5] - The basic earnings per share for the quarter was -¥0.5502, showing a 6.89% improvement from the previous year[5] - Total operating revenue for the current period reached ¥201,833,283.62, a significant increase from ¥79,247,029.95 in the previous period, representing a growth of approximately 154.5%[22] - The net loss for the current period was ¥400,731,032.38, compared to a net loss of ¥379,328,944.11 in the previous period, reflecting a deterioration in performance[23] - Basic and diluted earnings per share were both reported at -¥1.8554, compared to -¥1.6234 in the previous period, indicating a decline in shareholder value[24] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,884,888,739.39, reflecting a 6.57% increase from the previous year[5] - The company's total liabilities reached CNY 4,081,060,296.18, up from CNY 3,505,244,806.05, indicating a rise of approximately 16.4%[19] - The company's non-current liabilities decreased from CNY 637,512,104.04 to CNY 514,640,362.47, a reduction of approximately 19.3%[19] - The company's total liabilities and equity reached ¥2,884,888,739.39, compared to ¥2,707,062,422.60 in the previous period, showing an increase of approximately 6.6%[21] Cash Flow - The company reported a net cash flow from operating activities of -¥133,192,704.99, a decline of 19.52% compared to the previous year[5] - Cash flow from operating activities resulted in a net outflow of ¥133,192,704.99, worsening from a net outflow of ¥111,442,172.83 in the previous period[26] - Cash flow from investing activities showed a net outflow of ¥220,055,260.11, compared to a smaller outflow of ¥26,130,137.66 in the previous period[28] - Cash flow from financing activities generated a net inflow of ¥378,116,178.57, an increase from the previous period's inflow of ¥253,667,277.48[28] - The ending cash and cash equivalents balance was ¥38,416,329.98, down from ¥119,714,571.69 in the previous period[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,297[9] - Guangdong Ouhao Group holds a 21.99% stake in the company, with 47,498,448 shares pledged[9] Strategic Developments - The increase in revenue was attributed to a sustained rise in orders from overseas customers[8] - The company has signed a debt investment agreement for a total of CNY 100 million with Xinda Investment during the pre-restructuring period[12] - The company has designated 17 entities as financial investors for its restructuring, with 16 of them being independent and not related[13] - The court has approved the company's restructuring application, allowing it to continue operations during the restructuring period[14] - The company has received approval to extend the maturity of a CNY 300 million beneficial debt until December 31, 2025[16] - The company has terminated the implementation of its 2023 restricted stock incentive plan[14] Expenses - Total operating costs amounted to ¥556,235,812.91, up from ¥413,806,754.90, indicating an increase of about 34.4%[22] - The company reported an increase in research and development expenses to ¥2,889,835.21 from ¥26,367,875.61, reflecting a strategic focus on innovation despite overall losses[22] Non-Recurring Items - Non-recurring gains and losses totaled ¥1,022,923.24 for the quarter, with government subsidies contributing ¥424,496.74[6]

普蕊斯（上海）医药科技开发股份有限公司 2025 年第三季度报告 证券代码：301257 证券简称：普蕊斯 公告编号：2025-062 普蕊斯（上海）医药科技开发股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 普蕊斯（上海）医药科技开发股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 期增减 | | 比上年同期增减 | | 营业收入（元） | 218,910,71 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥126,443,232.77, representing a year-on-year increase of 3.56%[5] - The net profit attributable to shareholders for Q3 2025 was -¥7,537,730.77, a significant decrease of 534.25% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥15,850,705.00, down 508.87% year-on-year[5] - The basic earnings per share for Q3 2025 was -¥0.0188, reflecting a decline of 537.21% compared to the previous year[5] - The net profit for the current period is 9,399,842.40, a decrease of 5.07% compared to 9,902,927.86 from the previous period[21] - The total profit for the current period is 10,110,924.14, down 9.38% from 11,158,450.98 in the previous period[21] - The operating profit for the current period is 10,077,737.15, slightly down from 10,472,484.72 in the previous period[21] - The basic and diluted earnings per share for the current period are both 0.0234, down from 0.0246 in the previous period[21] Assets and Liabilities - The total assets at the end of Q3 2025 amounted to ¥2,790,885,467.87, an increase of 2.40% from the end of the previous year[5] - Total assets increased to ¥2,790,885,467.87 from ¥2,725,517,187.03, marking a growth of 2.40%[18] - Total liabilities rose to ¥1,024,759,499.30 from ¥868,101,437.11, reflecting an increase of 18.06%[18] - The company's total equity decreased to ¥1,766,125,968.57 from ¥1,857,415,749.92, a decline of 4.90%[18] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥19,600,893.57, down 44.30% from the previous year[5] - Cash flow from operating activities for the current period is 19,600,893.57, a decrease of 44.5% compared to 35,193,005.23 from the previous period[22] - Cash flow from investing activities shows a net inflow of 34,205,511.05, down from 408,315,248.82 in the previous period[22] - Cash flow from financing activities has a net inflow of 46,737,425.10, compared to a net outflow of 386,682,802.77 in the previous period[23] - The total cash and cash equivalents at the end of the period is 777,858,965.40, an increase from 518,573,031.87 at the end of the previous period[23] Expenses - The company reported a significant increase in sales expenses, which contributed to the decline in net profit[8] - Total operating costs decreased to ¥335,255,538.73 from ¥336,662,644.47, reflecting a reduction of 0.42%[20] - Operating costs specifically for goods sold were ¥155,727,261.42, down from ¥167,266,311.47, indicating a decrease of 6.93%[20] - Research and development expenses amounted to ¥69,070,735.32, a decrease of 17.25% from ¥83,429,418.51 in the previous period[20] - The company reported a financial expense of -¥2,245,863.34, an improvement compared to -¥3,681,104.46 in the previous period[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,665[10] - The number of restricted shares held by top executives decreased from 150,233,733 to 148,441,983, with a total of 1,791,750 shares released from restrictions during the period[13] Government Support - The company received government subsidies amounting to ¥3,536,523.42 during the reporting period[6] Other Comprehensive Income - The company reported a decrease in other comprehensive income after tax to -245,172.40 from -713,854.79 in the previous period[21] Sales Performance - Cash inflow from sales of goods and services is 361,874,584.12, an increase from 344,951,997.27 in the previous period[22]

Financial Performance - The company's operating revenue for the third quarter was ¥30,749,789.88, a decrease of 28.46% compared to the same period last year[3]. - The total profit for the third quarter was a loss of ¥18,338,008.92, with a year-to-date loss of ¥25,938,257.20[3]. - The net profit attributable to shareholders for the third quarter was a loss of ¥19,526,883.18, and the year-to-date loss was ¥29,377,855.95[3]. - The company experienced a 34.27% decline in operating revenue year-to-date, primarily due to decreased product sales and price reductions from centralized procurement policies[8]. - Total operating revenue for the first three quarters of 2025 was ¥90,432,870.13, a decrease of 34.2% compared to ¥137,579,847.20 in the same period of 2024[18]. - Net profit for the first three quarters of 2025 was a loss of ¥29,377,855.95, compared to a loss of ¥13,009,588.94 in 2024, representing a deterioration of 126.5%[19]. Research and Development - Research and development expenses totaled ¥12,727,608.42 for the quarter, accounting for 41.39% of operating revenue, an increase of 7.25 percentage points year-on-year[4]. - Research and development expenses for the first three quarters of 2025 were ¥42,058,199.29, an increase of 7.6% from ¥39,074,589.30 in 2024[18]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,721,101,815.28, a decrease of 1.82% from the end of the previous year[4]. - The total amount of current assets as of September 30, 2025, is approximately ¥2.94 billion, slightly increased from ¥2.93 billion in the previous year[14]. - Total assets amount to ¥3.72 billion, down from ¥3.79 billion in the previous year[14]. - Non-current assets total ¥783.24 million, a decrease from ¥854.34 million year-over-year[14]. - The total liabilities increased to ¥327,172,042.30 in 2025, compared to ¥153,063,328.61 in 2024, indicating a significant rise[16]. - The total equity attributable to shareholders decreased to ¥3,393,929,772.98 in 2025 from ¥3,636,886,762.51 in 2024, a decline of 6.7%[16]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥32,672,416.67, a decrease of 23.89% compared to the previous year[3]. - Cash inflow from operating activities totaled ¥172,091,272.35 in 2025, down 29.3% from ¥243,668,973.36 in 2024[22]. - The cash flow from sales of goods and services was ¥120,213,144.22 in 2025, down 24% from ¥158,023,714.74 in 2024[22]. - The net cash flow from operating activities was $32,672,416.67, a decrease of 24% compared to $42,926,358.23 in the previous period[23]. - The total cash outflow from operating activities was $139,418,855.68, compared to $200,742,615.13 previously, showing a reduction in operational cash outflows[23]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,435[11]. - The largest shareholder, Shanghai Zhijiang Pharmaceutical Co., Ltd., holds 64,969,560 shares, representing 33.81% of total shares[11]. - The company has a total of 14,638,308 shares in its repurchase account, accounting for 7.62% of total shares[13]. - The company has no significant changes in the participation of major shareholders in margin trading or securities lending[13]. Other Financial Metrics - The weighted average return on net assets was -0.56%, an increase of 0.47 percentage points compared to the previous year[4]. - The basic earnings per share for the third quarter was -¥0.10, with a year-to-date figure of -¥0.16[4]. - The company reported non-recurring gains and losses totaling ¥4,477,565.75 for the quarter[7]. - The company reported a financial expense of -¥31,340,122.83 in 2025, a significant improvement from -¥67,266,345.27 in 2024[18]. - The company recorded a credit impairment loss of ¥1,168,467.86 in 2025, compared to a recovery of -¥215,377.15 in 2024[19]. - The company paid $57,114,359.51 in employee compensation, which is lower than $78,188,799.34 in the previous period[23]. - The company experienced a foreign exchange loss of -$9,676,055.88, compared to -$10,932,424.75 in the prior period[23]. - The company has not disclosed any new strategies or future outlook in the provided documents[12].